Just One Question Podcast: S3 E6 – Biotech expert Seth and Nick discuss revolutionary regenerative medicine treatments

Seth Ettenberg and Nick discuss how technology is used to develop regenerative medicine for conditions such as Parkinson’s disease and Alzheimer’s disease.

Seth Ettenberg is CEO and President of BlueRock Therapeutics, a wholly owned subsidiary of Bayer. He’s a biotech entrepreneur, on the cutting edge of something called regenerative medicine.

Click Here To Listen

Related News

Press Releases

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial

January 13, 2025
Research Insights

How new modalities could evolve the treatment of Parkinson’s disease

November 13, 2024
Research Insights

Parkinson’s in Perspective: An Interview with Vikas Chinnan

October 2, 2024
Press Releases

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial

January 13, 2025
Research Insights

How new modalities could evolve the treatment of Parkinson’s disease

November 13, 2024
Research Insights

Parkinson’s in Perspective: An Interview with Vikas Chinnan

October 2, 2024
See All